NYSE: AVTRAvantor Inc Stock
$25.15-0.31 (-1.22%)
Updated Apr 25, 2024
AVTR Price
$25.15
Fair Value Price
N/A
Market Cap
$17.06B
52 Week Low
$16.63
52 Week High
$26.16
P/E
52.4x
P/B
3.25x
P/S
2.21x
PEG
0.35x
Dividend Yield
N/A
Revenue
$6.97B
Earnings
$321.10M
Gross Margin
33.9%
Operating Margin
9.98%
Profit Margin
4.6%
Debt to Equity
1.47
Operating Cash Flow
$870M
Beta
1.06
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
AVTR Overview
Avantor, Inc. provides products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries worldwide. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Zen Score
–
Industry Average (36)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AVTR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AVTR ($25.15) is trading below its intrinsic value of $27.52, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AVTR is poor value based on its earnings relative to its share price (52.4x), compared to the US market average (40.97x)
P/E vs Market Valuation
AVTR is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more AVTR due diligence checks available for Premium users.
Be the first to know about important AVTR news, forecast changes, insider trades & much more!
AVTR News
Valuation
AVTR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
52.4x
Industry
30.16x
Market
40.97x
AVTR is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
AVTR is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
AVTR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.25x
Industry
3.34x
AVTR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AVTR price to earnings growth (PEG)
For valuing profitable companies with growth potential
AVTR is good value based... subscribe to Premium to read more.
PEG Value Valuation
AVTR's financial health
Profit margin
Revenue
$1.7B
Net Income
$98.5M
Profit Margin
5.7%
AVTR's Earnings (EBIT) of $695.30M... subscribe to Premium to read more.
Interest Coverage Financials
AVTR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$13.0B
Liabilities
$7.7B
Debt to equity
1.47
AVTR's short-term assets ($2.38B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVTR's long-term liabilities ($6.24B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVTR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AVTR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$251.6M
Investing
-$50.0M
Financing
-$184.1M
AVTR's operating cash flow ($870.00M)... subscribe to Premium to read more.
Debt Coverage Financials
AVTR vs Specialty Chemical Stocks
Avantor Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.